Inmed launches thcv, expanding its portfolio of rare cannabinoids for the health and wellness sector

Vancouver, british columbia, june 09, 2022 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce it has launched b2b sales of the rare cannabinoid delta 9-dominant tetrahydrocannabivarin (“d9-thcv”) into the health and wellness sector via its wholly-owned subsidiary, baymedica llc (“baymedica”).
INM Ratings Summary
INM Quant Ranking